Whole-body MR in Staging Bone and Soft Tissue Metastases in Breast Cancer Patients(MetaMaRBo) (METAMARBO)
Prospective MR-imaging study : role of magnetic resonance (MR) and Diffusion weighted imaging (DWI) MR in staging and therapy assessment in breast cancer patients with bone metastases.
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Whole-body Magnetische Resonantie Voor Het Opsporen Van Bot- en Weke Delenmetastasen Bij patiënten Met Een Borstcarcinoom (MetaMaRBo)|
- Validation of whole body diffusion weighted MRI in breastcancer patients [ Time Frame: 6 months ] [ Designated as safety issue: No ]whole body MRI will be correlated to the nucleair bone scan and PET-CT
- Whole body MRI with diffusion weighted imaging is a reliable imaging tool for therapy assessment [ Time Frame: 12 months ] [ Designated as safety issue: No ]
|Study Start Date:||February 2011|
|Estimated Study Completion Date:||August 2013|
|Estimated Primary Completion Date:||April 2013 (Final data collection date for primary outcome measure)|
Breast cancer patients
Breast cancer patients
About 50 patients with a proven breast cancer and bone metastases will be included.
First step : staging
- nuclear bone scan
- Positron Emission Tomography (PET/CT)
- MR (whole body short tau inversion recovery (STIR)-sequence and T1-sequence and Diffusion weighted imaging (DWI),no contrast administration
- Validation of whole body diffusion weighted imaging in detection of bone metastases and visceral metastases, comparing to Bone scan en PET/CT results.
- To calculate cut-off values for DWI for bone and visceral metastases.
Second step : therapy follow-up/therapy assessment.
Two groups of patients (oncologist takes the decision about therapy)
- Patients treated by chemotherapy
- Patients treated by hormonal therapy
- on week 3, 12-16 and 52 in the chemotherapy or hormonal therapy-setting, a whole body MR (same protocol, no contrast) will be performed.
Whole body MR with DWI is useful and reliable to assess the treatment response.
|Contact: Steven Pansfirstname.lastname@example.org|
|University Hospitals Leuven||Recruiting|
|Leuven, Belgium, 3000|
|Contact: Steven Pans, MD 003216340505 email@example.com|
|Principal Investigator: Steven Pans, MD|
|Principal Investigator:||Steven Pans, MD||UZ Leuven Dept Radiology|